RxDoctor Payments Data

Matthew Coleman, MD

Gastroenterology · Cape Girardeau, MONPI 1922078088

Payments from drug & device makers

$9,000in general payments, 2019–2025

Across 459 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$911
  • Pfizer$667
  • Sanofi$486
  • plus $3K from 26 others

What the payments were for

  • Food & beverage$8,79598%
  • Education$2062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,000 in reported general payments places this provider in the 75th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$226,513
Medicare patients
367
Services billed
11,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide32$24,310
MounjaroTirzepatide13$11,911
Mesalamine ErMesalamine38$11,891
Mesalamine30$9,435
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates86$5,686
Sucralfate13$5,502
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C33$4,784
MovantikNaloxegol Oxalate12$4,236
SutabSod Sulf/Pot Chloride/Mag Sulf24$3,938
Pantoprazole Sodium318$3,257
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag21$2,544
LoperamideLoperamide Hcl15$717
Sulfasalazine15$213
Omeprazole14$140
Allopurinol11$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,506$24,31032 claims
Braintree Laboratories, Inc.Sutab, Suflave$174$6,48245 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$1,069$4,78433 claims
Redhill Biopharma Inc.Movantik$72$4,23612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →